Format

Send to

Choose Destination
Children (Basel). 2019 Jan 29;6(2). pii: E17. doi: 10.3390/children6020017.

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis.

Author information

1
Department of Dermatology, Hospital Universitario La Paz, 28046 Madrid, Spain. rauldelucas@gmail.com.
2
Dermatology Group Pedro Jaén, 28002 Madrid, Spain. cgmillan@gmail.com.
3
Medical Affairs Department, Cantabria labs, 28043 Madrid, Spain. azahara.perez@cantabrialabs.es.
4
Department of Dermatology, Clínica Universitaria de Navarra, 31008 Pamplona, Spain. emartero@unav.es.
5
Department of Dermatology, Clínica Universitaria de Navarra, 31008 Pamplona, Spain. predondo@unav.es.

Abstract

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and efficacy, a prospective, open-label, and multicenter study was carried out on patients diagnosed with mild to moderate AD. Transepidermal water loss (TEWL), clinical severity, Desquamation Index, Patient/Investigator Global Assessments, quality of life index, and tolerance were assessed. Adverse events were recorded. Daily application of the new treatment was well tolerated, and adverse events were absent. After 14 days, TEWL showed a 36.7% significant decrease (p = 0.035). At the end of the 28-day treatment, the Desquamation Index showed a reduction in 70% of patients; Eczema Area and Severity Index were reduced by 70.4% (p = 0.002); and skin irritation showed a significant reduction (p = 0.024). Likewise, Patient and Investigator Global Assessments reported a significant improvement in conditions and an overall global worsening when patients restarted their normal treatment. Parent's Index of Quality of Life Index significantly increased by 36.4% (p < 0.05) with Dermacare. In conclusion, a regular use of this new formulation can reduce the risk of relapse and extend the steroid-free treatment periods.

KEYWORDS:

atopic; dermatitis; emollient; epidermal barrier; filaggrin; moisturizer

PMID:
30700045
DOI:
10.3390/children6020017
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center